Investigational drug · Phase 2
JBI-778
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "JBI-778"
First trial start
2028
Apr 1, 2028
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JBI-778", any sponsor or status.
Conditions studied
As listed on its trial records.
- Brain Metastases From Solid Tumors
- Leptomeningeal Disease
- High Grade Glioma (HGG)
- Glioblastoma (GBM)
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JBI-778" as an intervention, largest first.
Jubilant Therapeutics Inc.Industry
NCT07751744 · 113 participants (planned) · Start Apr 1, 2028 · Primary completion Mar 31, 2030
Drug: JBI-778 · For: Brain Metastases From Solid Tumors; Leptomeningeal Disease; High Grade Glioma (HGG) and 1 more
Jubilant Therapeutics India LimitedIndustry
NCT07755397 · 30 participants (planned) · Start Aug 26, 2024 · Primary completion Mar 2028
Drug: JBI-778 · For: NSCLC Patients With EGFR Activating Mutation; Adenoid Cystic Carcinoma Metastatic; Adenoid Cystic Carcinoma of the Head and Neck
Sites: Surat, India; Bangalore, India; Mumbai, India · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Brain Metastases From Solid Tumors
- Intracerebroventricular of MT027 UCAR-T Cell targeting B7H3Phase 22 trials
T-MAXIMUM Pharmaceutical Inc · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Brain Metastases From Solid Tumors
- IAM1363Phase 21 trial
Iambic Therapeutics, Inc · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer
- RAD10118F-FPIAPhase 21 trial
Radiopharm Theranostics, Ltd · Brain Metastases From Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.